Decision Support · Side-by-side

Deep Genomics vs GenomeEditing AI (by Profluent). Side by side.

Compare pricing, strengths, and use cases so it is easier to pick the right fit.

Browse alternatives Browse workflows

Change tools

Comparison Ready

Deep Genomics

GenomeEditing AI (by Profluent)

Best overall

Neither Deep Genomics nor GenomeEditing AI is for everyday users — both are enterprise-grade tools for specialized biologists and drug developers. Deep Genomics wins for pharmaceutical teams needing end-to-end drug discovery from genomic data, while GenomeEditing AI is better for academic labs and biotechs designing custom CRISPR systems. The single biggest difference: Deep Genomics is a closed, full-service platform for RNA therapeutics, whereas GenomeEditing AI offers open-source models for gene-editing design.

Deep Genomics

#4200 of 3,826 Web

GenomeEditing AI (by Profluent)

#4246 of 3,826 Web

Scores at a glance

Deep GenomicsGenomeEditing AI (by Profluent)Practical Versatility

Onboarding Ease

Ecosystem Fit

Market Value

Choose Deep Genomics if

You work at a pharmaceutical company developing RNA-targeting drugs for rare genetic diseases
You have a team of computational biologists and access to proprietary patient genomic datasets
You need a partner to take a drug candidate from target discovery through IND filing
You are willing to pay for a full-service, closed-platform solution with no self-service option

Choose GenomeEditing AI (by Profluent) if

You are a CRISPR researcher or biotech founder designing novel gene-editing proteins
You have a Linux server or cloud credits to run generative models and molecular simulations
You want open-source transparency to validate and customize the AI's designs
You are exploring alternatives to existing CRISPR patents for therapeutic or agricultural applications

Key differences

Deep Genomics focuses on RNA therapeutics; GenomeEditing AI focuses on CRISPR protein design.
Deep Genomics is a closed, enterprise-only platform; GenomeEditing AI offers open-source models.
Deep Genomics requires a strategic partnership; GenomeEditing AI can be self-hosted from a public repository.
Deep Genomics has no mobile app or API; GenomeEditing AI also lacks both.
Deep Genomics is for drug discovery teams; GenomeEditing AI is for gene-editing researchers.
Pricing for both is opaque, but GenomeEditing AI has a free open-source entry point.

Facts side by side

	Deep Genomics	GenomeEditing AI (by Profluent)
Free plan
Mobile app
API access

Deep Genomics: strengths & weaknesses

Best-in-class accuracy for predicting how genetic variants affect RNA splicing
End-to-end drug design pipeline from variant to pre-clinical candidate
Proven partnerships with major pharmaceutical companies
No mobile app, no API, no public pricing — enterprise-only access
Requires specialized genomic data (FASTA, VCF, BAM) and a biology team to interpret results
Proprietary models mean you can't see or tweak how predictions are made
Onboarding involves a multi-step strategic partnership, not a sign-up form

GenomeEditing AI (by Profluent): strengths & weaknesses

First generative AI platform that designs entirely new CRISPR systems from scratch
Open-source primary models let you inspect and modify the code
Bypasses many existing CRISPR patents, which could save licensing costs
High experimental validation rate for designed proteins
No mobile app, no API — you need a powerful computer or server to run the models locally
Enterprise pricing is opaque; free tier is limited to the open-source model
Regulatory path for AI-designed gene-editing proteins is unclear and years away
Requires understanding of CRISPR biology and command-line tools for self-hosting

Common questions

Can I use Deep Genomics or GenomeEditing AI on my phone?

No. Neither tool has a mobile app or mobile-friendly interface. Both require desktop computers or servers to run.

Which tool is better for a small biotech startup with limited budget?

GenomeEditing AI is the better choice because its primary models are open-source and free to use, though you'll need computational resources. Deep Genomics is enterprise-only with no published pricing.

Do I need to know programming to use these tools?

Yes, for both. Deep Genomics requires a team of computational biologists to handle genomic data formats. GenomeEditing AI requires command-line skills to clone repositories and run models.

Are these tools approved by the FDA for drug design?

No. Neither tool is FDA-approved. They are research and development platforms. Any drug candidate designed with them must go through standard regulatory approval.

Can I use these tools for personal genetic testing (like 23andMe data)?

No. Both tools are designed for professional drug discovery and gene-editing research, not for personal health insights. They require specialized genomic data formats and biological expertise.

Both tools are powerful but inaccessible to everyday users — Deep Genomics is a closed enterprise drug discovery platform, while GenomeEditing AI offers open-source CRISPR design for researchers with bioinformatics skills.

If you're a non-technical person looking for an AI tool to use on your phone or laptop, neither Deep Genomics nor GenomeEditing AI is for you — they are specialized platforms for professional biologists. For gene-editing research with some technical skill, start with GenomeEditing AI's open-source models. For full-service RNA drug development, Deep Genomics is the only option, but you'll need a corporate partnership.

Visit Deep Genomics Visit GenomeEditing AI (by Profluent)

Detail pages: Deep Genomics · GenomeEditing AI (by Profluent)

Deep Genomics

GenomeEditing AI (by Profluent)

Free plan

Mobile app

API access